SCHEMBL3532851

SCHEMBL3532851

Cc1ccc(S(=O)(=O)N2CCc3c(OCCN4CCCCC4)cccc3C2C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 4/20 0.50
▸ ESR2 Q92731 4/20 0.50
▸ ALDH1A1 P00352 6/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ MMP1 P03956 2/20 0.44
▸ MMP2 P08253 2/20 0.44
▸ MMP7 P09237 2/20 0.44
▸ MMP9 P14780 2/20 0.44
▸ MMP12 P39900 2/20 0.44
▸ MMP14 P50281 2/20 0.44
▸ MMP15 P51511 2/20 0.44
▸ MMP16 P51512 2/20 0.44
▸ MMP26 Q9NRE1 2/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ FKBP1A P62942 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020682 0.88 LTA4H (0.45) ESR1ESR2MMP1MMP7KDM4E
SCHEMBL1020936 0.79 MMP1 (0.47) ESR1ESR2MMP1MMP2MMP7
SCHEMBL1020684 0.77 ESR1 (0.44) ESR1ESR2MMP1MMP7KDM4E
SCHEMBL5175084 0.76 ESR1 (0.42) ESR1ESR2ALDH1A1KMT2ALMNA
SCHEMBL1021774 0.74 LTA4H (0.43) ESR1ESR2ALDH1A1MMP1MMP2
SCHEMBL1023173 0.74 MMP1 (0.56) ESR1ESR2ALDH1A1MEN1KMT2A
SCHEMBL1021839 0.74 ESR1 (0.54) ESR1ESR2MMP1MMP2MMP7
SCHEMBL1020938 0.73 MMP1 (0.43) ESR1ESR2MMP1MMP2MMP7
SCHEMBL14415236 0.70 HTR6 (0.64) KDM4ESMN1; SMN2TSHR
SCHEMBL3536025 0.70 CACNA1F (0.41) ESR1ESR2ALDH1A1LMNAMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858619-B2 Substituted tetrahydroisochinolines as MMP inhibitors, related production method and use as medicine SANOFI-AVENTIS (FR) 2010-12-28 — — US disclosed
US-20080090821-A1 SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE SANOFI-AVENTIS (FR) 2008-04-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090821-A1 SUBSTITUTED TETRAHYDROISOCHINOLINES AS MMP INHIBITORS, RELATED PRODUCTION METHOD AND USE AS MEDICINE MMP9, MMP3, MMP2 ESR1 3179/4885ESR2 2188/4885ALDH1A1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback